Edwards Lifesciences Corp (NYSE:EW) Director William J. Phd Link sold 12,000 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $122.24, for a total transaction of $1,466,880.00. Following the completion of the transaction, the director now directly owns 24,596 shares of the company’s stock, valued at approximately $3,006,615.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Edwards Lifesciences Corp (EW) opened at $130.21 on Thursday. Edwards Lifesciences Corp has a 52 week low of $89.20 and a 52 week high of $138.48. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $27,560.00, a P/E ratio of 45.21, a PEG ratio of 1.87 and a beta of 0.63.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The company had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The firm’s revenue was up 15.7% compared to the same quarter last year. analysts expect that Edwards Lifesciences Corp will post 4.49 EPS for the current fiscal year.
A number of research firms have recently commented on EW. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $130.00 to $138.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Barclays increased their target price on shares of Edwards Lifesciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. JMP Securities increased their target price on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, February 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $155.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $162.00 target price on shares of Edwards Lifesciences in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $141.15.
Institutional investors have recently added to or reduced their stakes in the company. Cerebellum GP LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $128,000. Resources Investment Advisors Inc. increased its position in Edwards Lifesciences by 66.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares during the period. Exane Derivatives increased its position in Edwards Lifesciences by 381.3% during the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares during the period. MPS Loria Financial Planners LLC acquired a new stake in Edwards Lifesciences during the 2nd quarter valued at approximately $140,000. Finally, Dupont Capital Management Corp acquired a new stake in Edwards Lifesciences during the 3rd quarter valued at approximately $142,000. 81.11% of the stock is owned by institutional investors.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.